Hyderabad: Bharat Biotech today announced the quick ramp up of additional manufacturing capacities for Covaxin at Chiron Behring vaccines, Ankleshwar, Gujarat, a wholly owned subsidiary of Bharat Biotech.

The company plans to produce 200 millions doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. Product availability at Ankeshwar to commence from quarter four of year 2021.

Bharat Biotech had already deployed multiple production lines at its Hyderabad and Bengaluru campuses, Adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture Covaxin. This effectively takes the volumes upto – 1 Billion doses per Annum, with its own established campuses specialized for manufacturing inactivated viral vaccines under the highest levels of biosafety.

Chiron Behring Vaccines Pvt, Ltd, a 100 per cent subsidiary of Bharat Biotech International Ltd was formed as a result of the purchase of the vaccines business of Hoechst AG by Chiron Corporation USA. It is one of the largest manufacturers of high-quality rabies vaccines in the world. Chiron Behring Vaccines is a WHO pre-qualified manufacturer of rabies vaccines, eligible for supplies to UN agencies and has product registration in more than 20 countries. Acquiring of Chiron Behring Vaccines Pvt Ltd has established Bharat Biotech as a global leader in rabies vaccines manufacturer.